Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout

BMC Musculoskeletal Disorders

William J Taylor²  Anne Horne¹  Meaghan E House¹  Nicola Dalbeth¹ 

[1] Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd, Grafton, New Zealand;Department of Medicine, University of Otago Wellington, PO Box 7343, Wellington, 6242, New Zealand

关键词: Creatinine;    Kidney;    Tophus;    Gout;   

Others  :  1128999
DOI  :  10.1186/1471-2474-14-363

 received in 2013-09-03, accepted in 2013-12-18,  发布年份 2013

【 摘 要 】

Background

Although typically a late feature of gout, tophi may present early in the course of disease. The aim of this study was to identify factors associated with the presence of early tophaceous disease.

Methods

People with gout for <10 years were prospectively recruited, and had a comprehensive clinical assessment including examination for subcutaneous tophi. The clinical factors independently associated with the presence and number of tophi were analyzed using regression models.

Results

Of the 290 participants, there were 47 (16.2%) with clinically apparent tophi. In univariate analysis, those with tophi were older, were more frequently taking diuretics and colchicine prophylaxis, and had lower creatinine clearance. The association between the presence of tophi and creatinine clearance was strongest in those with creatinine clearance ≤30 ml/min. In logistic regression analysis, creatinine clearance ≤30 ml/min was associated with the presence of tophi, even after adjusting for ethnicity, corticosteroid use, colchicine use and diuretic use (multivariate adjusted odds ratio 7.0, p = 0.005). Participants with tophi reported higher frequency of gout flares, pain scores, patient global assessment scores, and HAQ scores.

Conclusions

The presence of tophi is associated with more symptomatic disease in people with gout for <10 years. Creatinine clearance is independently associated with early presentation of subcutaneous tophi.

【 授权许可】

   
2013 Dalbeth et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen FM, Cornish J: Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 2010, 62(5):1549-1556.
• [2]Hench PS: The diagnosis of gout and gout arthritis. J Lab Clin Med 1936, 22:48-55.
• [3]Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL: Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984, 27(4):468-471.
• [4]Wordsworth BP, Mowat AG: Rapid development of gouty tophi after diuretic therapy. J Rheumatol 1985, 12(2):376-377.
• [5]Raso AA, Sto Nino OV, Li-Yu J: Does prolonged systemic glucocorticoid use increase risk of tophus formation among gouty arthritis patients? Int J Rheum Dis 2009, 12(3):243-249.
• [6]Baethge BA, Work J, Landreneau MD, McDonald JC: Tophaceous gout in patients with renal transplants treated with cyclosporine A. J Rheumatol 1993, 20(4):718-720.
• [7]Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM: Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 2007, 46(12):1804-1807.
• [8]Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D: Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 2012, 10:117. BioMed Central Full Text
• [9]Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, McQueen FM: Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009, 68(8):1290-1295.
• [10]Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E: Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014, 73(1):177-182.
• [11]Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20(3):895-900.
• [12]Horne R, Weinman J: Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999, 47(6):555-567.
• [13]Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ: Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken) 2011, 63(11):1605-1612.
• [14]Wolfe F, Michaud K, Pincus T: Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 2004, 50(10):3296-3305.
• [15]Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16(1):31-41.
• [16]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: modification of diet in renal disease study group. Ann Intern Med 1999, 130(6):461-470.
• [17]Scott JT, Holloway VP, Glass HI, Arnot RN: Studies of uric acid pool size and turnover rate. Ann Rheum Dis 1969, 28(4):366-373.
• [18]Schreiner O, Wandel E, Himmelsbach F, Galle PR, Marker-Hermann E: Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 2000, 15(5):644-649.
• [19]Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al.: American college of rheumatology guidelines for management of gout: part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012, 64(10):1431-1446.
• [20]Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47(4):356-360.
• [21]Roddy E, Zhang W, Doherty M: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007, 66(10):1311-1315.
• [22]Harrold LR, Mazor KM, Negron A, Ogarek J, Firneno C, Yood RA: Primary care providers’ knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford) 2013, 52(9):1623-1629.
• [23]Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, Nicolaou S: Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009, 68(10):1609-1612.
• [24]Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR: Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009, 36(10):2346-2355.